| Post date: 2021/04/15 |
Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have been proposed that are effective in the regeneration of damaged lungs in severe COVID-19 patients. In this regard, In a randomized, double-blind, placebo-controlled phase 2 trial, Shi et al. illustrated that UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 patients with lung damage.
Mesenchymal stem cells (MSCs) are non-hematopoietic cells with immune-modulatory, regenerative, and differentiation properties. And their efficacy as a therapeutic method against pathological changes of the lung induced by the influenza virus. moreover, The safety and potential efficacy of MSC have also been evaluated in patients with acute respiratory distress syndrome (ARDS). The immunomodulatory and regenerative properties of MSCs offer a potential cellular therapeutic option for lung damage in patients with COVID-19.
Read more
Mesenchymal stem cells (MSCs) are non-hematopoietic cells with immune-modulatory, regenerative, and differentiation properties. And their efficacy as a therapeutic method against pathological changes of the lung induced by the influenza virus. moreover, The safety and potential efficacy of MSC have also been evaluated in patients with acute respiratory distress syndrome (ARDS). The immunomodulatory and regenerative properties of MSCs offer a potential cellular therapeutic option for lung damage in patients with COVID-19.
Read more
View: 1103 Time(s) |
Print: 341 Time(s) |
Email: 0 Time(s) |
0 Comment(s)
